This article uses bare URLs, which are uninformative and vulnerable to link rot. Please consider converting them to full citations to ensure the article remains verifiable and maintains a consistent citation style. Several templates and tools are available to assist in formatting, such as reFill (documentation) and Citation bot (documentation). (August 2022) (Learn how and when to remove this message)
|
Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA).[1][2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H28N8O2 |
Molar mass | 460.542 g·mol−1 |
3D model (JSmol) | |
| |
|
Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study.[3] Currently running clinical trials[4] were continued for patients exhibiting benefit.
This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |